SCHEMBL1489754

SCHEMBL1489754

Nc1cc(-c2nccs2)nc(-c2ccccn2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.50
L3MBTL1 Q9Y468 3/20 0.50
ALOX15 P16050 1/20 0.50
TDP1 Q9NUW8 2/20 0.49
ADORA2A P29274 5/20 0.47
HSP90AA1 P07900 1/20 0.46
ADORA1 P30542 4/20 0.46
RAB9A P51151 4/20 0.44
NPC1 O15118 4/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
TP53 P04637 2/20 0.43
MAPK14 Q16539 1/20 0.42
CYP19A1 P11511 1/20 0.42
PDPK1 O15530 1/20 0.41
HTT P42858 2/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.40
LMNA P02545 1/20 0.40
PPP1CA P62136 1/20 0.40
GLA P06280 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1489975 0.84 HSP90AA1 (0.54) ADORA2AHSP90AA1ADORA1RAB9APDPK1
SCHEMBL30835039 0.81 KDM4E (0.63) KDM4EL3MBTL1ALOX15TDP1ADORA2A
SCHEMBL5017693 0.81 HSP90AA1 (0.47) KDM4EL3MBTL1TDP1ADORA2AHSP90AA1
SCHEMBL452340 0.79 KDM4E (0.57) KDM4EL3MBTL1ALOX15TDP1HSP90AA1
Ammonia Solution, Strong SCHEMBL28442530 0.77 KDM4E (0.55) KDM4EL3MBTL1ALOX15TDP1HSP90AA1
Fluoride SCHEMBL27903468 0.77 KDM4E (0.55) KDM4EL3MBTL1ALOX15TDP1HSP90AA1
SCHEMBL5026240 0.76 KDM4E (0.58) KDM4EL3MBTL1ALOX15TDP1ADORA2A
SCHEMBL7264634 0.76 ADORA2A (0.68) KDM4EL3MBTL1ALOX15TDP1ADORA2A
SCHEMBL5016124 0.76 ADORA2A (0.50) KDM4EADORA2AHSP90AA1ADORA1RAB9A
SCHEMBL30252544 0.75 ADORA2A (0.43) KDM4EL3MBTL1ALOX15ADORA2AHSP90AA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1888565-B1 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL SA (ES) 2011-03-23 EP disclosed
US-20080275064-A1 Substituted Pyrimidines as Adenosine Receptor Antagonists ALMIRALL, S.A. (ES) 2008-11-06 US disclosed
EP-1888565-A2 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS NEUROCRINE BIOSCIENCES, INC. (US) 2008-02-20 EP disclosed
WO-2006110884-A2 2, 6-DI (HETERO) ARYL -4-AMIDO-PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS NEUROCRINE BIOSCIENCES, INC. (US) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080275064-A1 Substituted Pyrimidines as Adenosine Receptor Antagonists ADORA2A, ADORA3, ADORA1 KDM4E 4317/4885L3MBTL1 3454/4885ALOX15 1774/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.